Staging of tau deposition in idiotypic isocortices using flortaucipir PET in Alzheimer’s disease pathology. Josephs et al.
Description
Analysis data sets and R scripts for data analysis and figures.
Files
Steps to reproduce
We included 155 participants recruited from Mayo Clinic, Rochester, MN, who had flortaucipir PET imaging during life, had died and undergone an autopsy evaluation between 8/28/2016 and 5/5/2024, and had AD (Thal Aβ phase of 1-5 16 and Braak NFT stage 0-VI). Participants were excluded if β-amyloid deposition was absent (i.e., Thal phase = 0) or if they had a pathological diagnosis of frontotemporal lobar degeneration (FTLD) or another primary pathological diagnosis. All 155 participants and 29 additional validation cases had been enrolled into one of three NIH funded cohort studies including the Mayo Clinic Alzheimer’s Disease Research Center (PI: Boeve), the Mayo Clinic Study of Aging (PI: Petersen) and the Neurodegenerative Research Group (PIs: Josephs/Whitwell). Flortaucipir standardized uptake value ratios (SUVRs) were calculated for the motor, somatosensory, auditory, and visual isocortical regions using the Human Brainnetome atlas. The motor cortex was also subdivided into four subregions (Brodman area 4 head/face (A4hf), upper limb (A4ul), trunk (A4t), and tongue/larynx (A4tl) regions) and similarly the somatosensory cortex was subdivided into four subregions (Brodman area 1, 2 and 3 upper limb & head and face region (A1/2/3ulhf), tongue/larynx (A1/2/3tonla), trunk (A1/2/3tru), and Brodman area 2 (A2)). We also assessed the entorhinal cortex (ERC) and inferior temporal lateral (ITL) gyrus given that these regions are affected at early Braak NFT stages.
Institutions
- Mayo ClinicMinnesota, Rochester